A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

May 11, 2022

Study Completion Date

May 22, 2022

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

DZD8586

Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

DRUG

Placebo

A single oral dose of placebo will be given.

Trial Locations (1)

Frontage Clinical Service 200 Meadowlands Parkway, Secaucus